Research community previously filed under “Molecular Biology”

SGLT2 Inhibitors and Electrolyte Management in Diabetes, Heart Failure, and Kidney Disease

Mostly in the field Electrolyte Metabolism, SGLT2 Inhibitors, and Nutritional Biochemistry (41% of its papers), one of 6 communities there

Papers 47,593
Elements 3
Keywords & sectors 13
Leading venue Journal of Biological Chemistry

SGLT2 Inhibitors and Electrolyte Management in Diabetes, Heart Failure, and Kidney Disease

This community focuses on the clinical application of sodium-glucose cotransporter-2 inhibitors and the management of sodium and potassium balance in patients with type 2 diabetes, heart failure, and chronic kidney disease.

The research centers on the pharmacological effects of SGLT2 inhibitors on glucose regulation, blood pressure, and renal function. A significant portion of the work examines the interplay between dietary sodium intake, serum potassium levels, and cardiovascular outcomes. Studies frequently address the risk of diabetic ketoacidosis and the management of ejection fraction in heart failure patients. The literature also includes substantial analysis of lithium therapy in bipolar disorder, reflecting the community's broad focus on electrolyte-sensitive conditions. Methodologies range from randomized controlled trials and systematic meta-analyses to case reports and large-scale prevalence studies, all aimed at optimizing treatment protocols for these interconnected metabolic and cardiovascular disorders.

This community represents 5.7% of all sodium research and 5.7% of all potassium research, with 18,441 and 11,843 papers respectively. It also accounts for 2.9% of lithium research, comprising 7,406 papers.

The community comprises 47,593 papers, published primarily in the Journal of Biological Chemistry, The Lancet, and Hypertension.

Recent work continues to focus on the cardiovascular and renal benefits of SGLT2 inhibitors, including perioperative management and combination therapies for chronic kidney disease. Newer studies also address the metabolic effects of GLP-1 agonists and the mechanisms of diabetic kidney disease.

Recurring themes in the literature

Phrases that recur across this community's paper titles -- a quick map of its sub-topics, drawn straight from the titles themselves.

  • heart failure 1107
  • sodium glucose 1013
  • type diabetes 959
  • kidney disease 749
  • cotransporter inhibitors 715
  • sodium-glucose cotransporter 631
  • blood pressure 623
  • chronic kidney 577
  • glucose cotransporter 515
  • sodium-glucose cotransporter-2 504
  • cotransporter-2 inhibitors 455
  • case report 446
  • diabetes mellitus 440
  • sodium potassium 416
  • systematic meta-analysis 357
  • sodium intake 345
  • patients type 343
  • bipolar disorder 305
  • serum potassium 247
  • randomized controlled 243
  • ejection fraction 235
  • urinary sodium 230
  • co-transporter inhibitors 223
  • dietary sodium 222

Papers behind this description

Most cited
Signal Transduction and Targeted Therapy · 2024 · 593 citations
New England Journal of Medicine · 2024 · 705 citations
New England Journal of Medicine · 2025 · 369 citations
New England Journal of Medicine · 2025 · 284 citations
Hypertension · 2025 · 254 citations
Newest
New England Journal of Medicine · 2025 · 155 citations
Nature Reviews Endocrinology · 2025 · 76 citations
The Lancet · 2026 · 46 citations
Nature Reviews Endocrinology · 2025 · 36 citations
British Journal of Anaesthesia · 2026 · 25 citations

A sample from the 13 papers behind this description. Create a free account to see them all.